Market Vectors® Pharmaceutical ETF
An Easier Way to Understand the Pharma Industry
In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
GlaxoSmithKline Stock Has Increased ~15% in 2018
On November 19, GlaxoSmithKline’s stock price closed at $40.83, which represents ~1.21% growth from its close of $40.34 on November 16.
Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
Jazz Pharmaceuticals’ Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017.
A Performance Overview of JNJ’s Beauty and OTC Businesses
Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017.
A Look at Novartis’s Valuation on October 9
Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue.
Analyzing Eli Lilly’s Q2 2018 Revenue Trend
Eli Lilly and Company surpassed Wall Street analysts’ estimates in the second quarter and reported a 9% YoY (year-over-year) rise in revenue.
Novartis’s Alcon in Q2 2018
Alcon, Novartis’s (NVS) eye care business, reported a 7% growth YoY (year-over-year) in revenues to ~$1.82 billion during Q2 2018.
Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018
GlaxoSmithKline’s (GSK) Vaccines segment includes its influenza, meningitis, shingles, and established vaccines.
Merck Witnessed 5% Growth in Q2 2018
Merck (MRK) generated revenues of $10.5 billion in the second quarter, reflecting ~5.0% year-over-year growth.
Novartis’s Q2 2018 Earnings: Alcon
Alcon, the eye care business of Novartis AG (NVS), reported revenues of ~$1.82 billion in Q2 2018, a 7% growth year-over-year.
Some Recent Pharmaceutical Mergers and Acquisitions
The US pharmaceutical sector comprises drug manufacturers, drug marketers, and biotechnology companies. Let’s look at pharmaceutical stocks’ performance in June.
How Pfizer’s Business Segments Have Performed
As discussed, Pfizer’s (PFE) business is divided into two business segments, Innovative Health and Essential Health.
What Are Valeant’s Key Developments since May?
On May 8, Valeant announced its name change to Bausch Health Companies in July. The name change will introduce a new corporate brand identity.
A Closer Look at Novartis’s Innovative Medicine Business
Novartis’s (NVS) Innovative Medicines business, which comprises its Novartis Pharmaceuticals and Novartis Oncology products, reported revenue of $8.4 billion in the first quarter, with operating revenue and foreign exchange contributing 6% growth each.
AstraZeneca’s 1Q18 Estimates: Respiratory Products
AstraZeneca’s (AZN) growth platforms include its Respiratory segment, which is expected to report growth in revenue during 1Q18.
Merck and AstraZeneca Announced EMA Approval for Lynparza
Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.
How Merck’s Human Vaccines Business Performed in 1Q18
In 1Q18, Merck’s (MRK) human vaccines business saw its total revenue grow 4.2% YoY (year-over-year) to $1.5 billion from $1.4 billion.
Sanofi Misses Wall Street Estimates for 1Q18 Revenues
Sanofi (SNY) missed Wall Street analysts’ estimates for revenues today but beat estimates for earnings per share.
These Pharma Stocks Offer the Most Upside Potential
In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.
Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
Analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
How GlaxoSmithKline Stock Performed in 1Q18
GlaxoSmithKline stock has risen ~6.4% in 1Q18, while its stock has risen ~12.6% YTD (year-to-date) as of April 6, 2018.
Analysts’ Recommendations for Pfizer in March 2018
Pfizer (PFE) surpassed Wall Street analysts’ consensus estimate for EPS (earnings per share) in 4Q17, reporting EPS of $0.62 compared to the estimate of $0.56.
How Novartis’s Sandoz Performed in 4Q17
Sandoz reported flat revenues at ~$2.6 billion during 4Q17 as compared to 4Q16.
What’s Novartis’s Valuation in March 2018?
Novartis reported earnings per share of $1.21 on revenues of ~$12.9 billion in 4Q17.
What’s AstraZeneca’s Valuation in March 2018?
AstraZeneca surpassed Wall Street analysts’ estimates with EPS of $1.03 on revenues of ~$5.8 billion in 4Q17.
Sanofi’s Valuations in February 2018
Sanofi (SNY) reported revenues of ~8.7 billion euros in 4Q17, a decline of ~2.0% in revenues compared to ~8.9 billion euros in 4Q16.
Sanofi Pasteur’s 4Q17 Performance
Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17, reflecting 8.7% growth in operating revenues compared to 4Q17.
GlaxoSmithKline’s Valuations after Its 4Q17 Earnings
On February 15, 2018, GlaxoSmithKline traded at a forward PE multiple of 12.9x, which is lower than the industry average of 13.3x.
Inside Valeant Pharmaceuticals’ Recent Divestments
Valeant Pharmaceuticals (VRX) was granted the worldwide exclusive licensing rights for manufacturing and selling the EyeGate 2 delivery system.
Highlights of Sanofi’s 3.9 Billion Euro Ablynx Acquisition
On January 29, 2018, Sanofi announced its acquisition of Belgium-based Ablynx for 45 euros per share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash.
Novartis’s 4Q17 Earnings: Innovative Medicines Business
Novartis’s (NVS) Innovative Medicines business reported 4.0% growth in operating revenues, while there was a 2.0% positive impact of foreign exchange in 4Q17.
Analyst Ratings and Recommendations for Merck & Co.
Wall Street analysts estimate Merck & Co.’s (MRK) top line to increase 3.7% to $10.5 billion for 4Q17 compared to $10.1 billion in 4Q16.
Dolutegravir Franchise to Drive GlaxoSmithKline’s HIV Portfolio
In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 1.1 billion pounds from the sale of its HIV products.
Tasigna Could Boost Novartis’s Revenue Growth in 2018
In 1Q17, 2Q17, and 3Q17, Tasigna generated revenues of $411 million, $463 million, and $482 million, respectively.
Novartis Receives 2 Breakthrough Therapy Designations in January
In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.
Behind Novartis’s 4Q17 Earnings: Why Some Expect Revenue Growth
Analysts expect Novartis’s revenues to rise ~3.9% to $12.8 billion in 4Q17, driven by growth in operating revenues across all three segments.
Johnson & Johnson’s Consumer Segment: 4Q17 Estimates
Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International.
How Teva Pharmaceutical Is Realigning Organizational Structure
On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years.
Venclexta Could Be Significant Driver for Roche in 2018
Venclexta (venetoclax) is used for the treatment of individuals with chronic lymphocytic leukemia (or CLL) with 17p deletion who previously underwent at least one therapy.
Mylan’s Valuation in January 2018
Mylan (MYL) is a leading pharmaceutical company with over 1,400 generic and specialty pharmaceutical products in its portfolio.
Valeant on the Street: Analyst Recommendations in December 2017
Of the 19 analysts tracking Valeant Pharmaceuticals in December 2017, two recommended a “strong buy,” while another two of recommended a “buy.”
How Valeant Subsidiary Bausch + Lomb Performed in 3Q17
In 3Q17, Valeant Pharmaceuticals’ Bausch + Lomb, generated revenues of $1.25 billion, which reflected a ~1% growth on a YoY basis.
How Did Novo Nordisk’s NovoMix and Human Insulin Perform in 2017?
In 3Q17, Novo Nordisk’s (NVO) NovoMix reported revenues of 2.4 billion Danish krone (or DKK), which reflected ~1% growth on year-over-year (or YoY) basis.
How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
How Is Johnson & Johnson’s Xarelto Positioned after 3Q17?
In 3Q17, Johnson & Johnson’s (JNJ) Xarelto generated revenues of $635 million, a ~20% increase on a year-over-year (or YoY) basis and a 1% decline quarter-over-quarter.
Behind Sanofi’s Diabetes and Cardiovascular Portfolio in 3Q17
Sanofi’s (SNY) diabetes and cardiovascular portfolio reported revenues of 1.67 billion euros for 3Q17, representing a 9.1% YoY fall in operating revenues.
How AstraZeneca’s Business Segments Performed in 3Q17
The oncology segment reported revenues of $1.0 billion during 3Q17, 19% growth in operating revenues as compared to 3Q16.
How AstraZeneca’s Duaklir and Bevespi Performed in 2017
In 3Q17, Bevespi generated revenues of $4.0 million compared to $3.0 million in 2Q17.
An Overview of AstraZeneca’s Oncology Drug Faslodex after 3Q17
In November 2017, the FDA approved label expansion for AstraZeneca’s Faslodex (fulvestrant).
A Look at Bristol-Myers Squibb’s Revenue in 3Q17
Bristol-Myers Squibb’s 3Q17 performance Bristol-Myers Squibb (BMY) reported EPS (earnings per share) of $0.75 in 3Q17, missing analysts’ estimate of $0.77. However, it surpassed their revenue estimate of $5.2 billion, reporting revenue of $5.3 billion. Revenue and EPS The above graph shows Bristol-Myers Squibb’s revenue over the last few quarters. In 3Q17, it saw revenue growth of 6.7% […]
GlaxoSmithKline’s Vaccines Business in 3Q17
GlaxoSmithKline’s (GSK) Vaccines business reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.
How Has Pfizer’s Internal Medicine Portfolio Performed in 2017?
In 3Q17, Pfizer’s (PFE) Lyrica reported revenues of $1.3 billion, which is ~4% growth on a year-over-year (or YoY) basis and 2% growth on a quarter-over-quarter basis.
Teva on Women’s Health—And Other Recent Developments
Teva’s Women’s Health segment reported 3Q17 revenues of $119 million, which was ~9% higher YoY (year-over-year) and 3% higher QoQ (quarter-over-quarter).
A Look into the Performance of Merck’s Vaccine Portfolio in 3Q17
Gardasil revenue In 3Q17, Merck’s (MRK) Gardasil and Gardasil 9 generated revenue of $675 million, which reflected a ~22% fall YoY (year-over-year) and ~44% growth QoQ (quarter-over-quarter). Lower sales in the US market primarily led to the fall in Gardasil revenue between 3Q16 and 3Q17. In 3Q17, Merck opted to borrow Gardasil 9 doses from the CDC’s […]
How AstraZeneca’s Growth Platforms Performed in 3Q17
The Respiratory segment reported a 2% fall in revenues at constant exchange rates to ~$1.1 billion during 3Q17.
How Did Novartis Subsidiaries Alcon and Sandoz Perform in 3Q17?
In 3Q17, Novartis (NVS) subsidiary Alcon generated revenues of $1.5 billion, which was ~6% higher YoY (year-over-year) and 1% higher QoQ.
Behind Novartis’s Established Medicine Performance in 3Q17
In 3Q17, Novartis’s (NVS) Galvus reported revenues of ~$310 million, which was ~1% higher YoY (year-over-year).
Understanding Sanofi’s Revenues by Segment in 3Q17
Sanofi reports its business in two segments: Human Pharmaceuticals and Sanofi Pasteur, or the Human Vaccines segment.
Behind Pfizer’s Corporate and Pipeline Developments in 3Q17
In October, Pfizer announced that it’s reviewing strategic alternatives, including full or partial separation through sale or a spin-off of its consumer healthcare business.
Behind Merck’s Performance in 3Q17
MRK stock rose ~0.6% in 3Q17 and has risen ~7.7% YTD (year-to-date) as of October 16.
A Look at the Market Caps of the Pharma Stocks under Review
In this article, we’ll take a look at the market caps of those pharmaceutical companies that have surpassed the S&P 500 Index so far in 2018.
Zoetis Stock: Performance in 3Q17
Zoetis stock has risen 2.2% in 3Q17. It has risen ~22.5% year-to-date as of October 20, 2017.
Changes in GlaxoSmithKline’s Valuation
As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.
Bristol-Myers Squibb’s Virology Portfolio
Bristol-Myers Squibb’s (BMY) virology portfolio includes products for the treatment of chronic virus infections like Hepatitis B virus infections, Hepatitis C virus (or HCV) infections, and HIV infections.
Xultophy Could Substantially Boost Novo Nordisk’s Revenue Growth
In the first half of 2017, Novo Nordisk’s (NVO) Xultophy generated revenues of DKK (Danish kroner) 284.0 million.
Why Cosentyx Could Significantly Drive Novartis’s Revenue Growth
In 1H17, Novartis’s (NVS) Cosentyx generated revenues of around $900 million compared to $436 million in 1H16.
An Update on Novartis’s Sandostatin, Afinitor, and Exjade
In 1H17, Novartis’s (NVS) Sandostatin generated revenues of around $789 million, which reflected a ~4% decline on a year-over-year (or YoY) basis.
TEVA Depends on This for Revenue Growth
In 1H17, Teva Pharmaceutical’s (TEVA) Copaxone reported revenues of ~$2.1 billion, or ~7% lower YoY (year-over-year).
How Merck’s Gardasil and Other Human Vaccines Performed in 2Q17
Merck’s (MRK) Gardasil franchise includes vaccines for the prevention of certain strains of HPV infections that are sexually transmitted.
Where Jazz Pharmaceuticals’ Erwinaze and Prialt Are Positioned after 2Q17
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Erwinaze generated revenues of ~$49 million, which represents a ~1% fall YoY and a ~4% fall QoQ.
Performance of AstraZeneca’s Other Products in 2Q17
AstraZeneca’s Other Products segment’s revenues fell 12% at constant exchange rates to ~$1.1 billion during 2Q17.
Performance of AstraZeneca’s Growth Platforms in 2Q17
Emerging markets such as China, Brazil, India, Russia, Mexico, and Turkey reported revenues of ~$1.4 billion during 2Q17, representing 2% growth at constant exchange rates from 2Q16.
Performance of Eli Lilly’s Neuroscience Products in 2Q17
Cymbalta’s sales totaled $206.6 million during 2Q17, a 13.0% decline compared to sales of $236.5 million in 2Q16.
Changes in GlaxoSmithKline’s Valuation after 2Q17
As of August 30, 2017, GlaxoSmithKline is trading at a forward PE multiple of 13.3x, which is slightly lower than the industry average of 15.5x.
How Novartis’s Sandoz Performed in 2Q17
Novartis’s Sandoz reported revenues of nearly $2.5 billion in 2Q17, representing ~20% of NVS’s total revenues.
Johnson & Johnson’s Medical Devices Segment in 2Q17
Medical devices segment Johnson & Johnson’s (JNJ) medical devices segment reported revenue of $6.7 billion in 2Q17, a growth of 4.9% from the revenue of $6.4 billion reported in 2Q16. This figure included 5.9% growth in operating revenue, and was partially offset by a 1% foreign exchange impact. Cardiovascular care franchise The cardiovascular care franchise […]
Jazz Pharmaceuticals Is Focused on Label Expansion of Defitelio
Defitelio could help Jazz Pharmaceuticals become a prominent player not only in the treatment but also in the prevention of post-HSCT complications.
JAZZ Is Focused on Increasing Market Adoption of Defitelio
Jazz Pharmaceuticals (JAZZ) expects quarterly variability in Defitelio sales as the drug targets hepatic veno-occlusive disease (or VOD), an ultra-rare condition.
Inside Jazz’s Net Profit Margin Expectations for 2017
For 2Q17, Jazz Pharmaceuticals (JAZZ) reported revenues close to $394 million, which represented a YoY growth of ~3% and sequential growth ~5%.
Sanofi’s Revenue Growth in 2Q17
Sanofi’s revenue in 2Q17 At constant exchange rates, Sanofi (SNY) reported revenue growth of ~5.5% between 2Q16 and 2Q17, with revenue rising to 8.7 billion euros from 8.1 billion euros. Structure of the group The above chart shows Sanofi’s segment-wise revenue over the last few quarters. In 2016, Sanofi reorganized itself into five business units: Sanofi […]
Pfizer’s Important Product Developments in 2Q17
Pfizer’s (PFE) innovative health business and essential health business are focusing on growth. To strengthen the innovative health business, the company is focusing on the development of new drugs…
GlaxoSmithKline’s 2Q17 Earnings: Business Segments
GSK reported operational growth of 3% in its revenues to ~7.3 billion pounds for 2Q17.
Bristol-Myers Squibb’s 2Q17 Earnings: Opdivo
Bristol-Myers Squibb’s (BMY) blockbuster drug Opdivo reported revenue of $1.2 billion in 2Q17, a 42% rise compared to $840 million in 2Q16.
Eli Lilly in 2Q17: Performance of New Products
For 2Q17, Basaglar sales were $86.6 million. Of that, $60.0 million was from sales in the US markets, while $27.0 million was from international sales.
Analysts’ Recommendations for AstraZeneca in 2Q17
Wall Street analysts expect AstraZeneca’s top line to fall ~9.5% to $5.1 billion in 2Q17, compared to $5.6 billion in 2Q16. Its earnings per share are expected to be $0.42 in 2Q17.
Inside GlaxoSmithKline’s 2Q17 Earnings Estimates
For 2Q17, analysts estimate that GSK’s revenues will rise ~11.4% to ~7.3 billion pounds, as compared to ~6.5 billion pounds for 2Q16.
Foreign Exchange Impacts Novartis’s Growth in 2Q17
In its earnings release on July 8, 2017, Novartis (NVS) reported flat revenues at constant currencies for 2Q17.
Johnson & Johnson: Consumer Products in 2Q17
The consumer segment Johnson & Johnson’s (JNJ) consumer segment revenue rose 1.7% to $3.5 billion in 2Q17, compared with $3.4 billion in 2Q16. This rise includes operational growth of 2.3%, which was offset by a 0.6% impact of foreign exchange. Baby care franchise The baby care franchise reported revenue of $494 million in 2Q17, a […]
Novartis’s 2Q17 Earnings: Analyst Estimates
Novartis is set to release its 2Q17 earnings on July 18, 2017. Analysts estimate EPS (earnings per share) of $1.18 and revenues of $12.3 billion.
Analysts’ Latest Recommendations for Johnson & Johnson
Johnson & Johnson (JNJ) missed Wall Street analysts’ revenue estimates in 1Q17. It reported revenue of $17.8 billion in the quarter.
Farxiga Could See Robust Demand in International Markets in 2017
In 1Q17, AstraZeneca’s (AZN) Farxiga reported sales of $42 million in emerging markets, which equals year-over-year growth of ~100% on a reported basis.
What We Can Expect from Eli Lilly and Company in 2Q17
A look at Eli Lilly and Company Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a US pharmaceutical company focused on human pharmaceuticals and animal health. Stock price performance Eli Lilly’s stock price has fallen ~4.4% in 2Q17. However, the stock price had risen 10.9% year-to-date as of July 7, 2017. Analysts’ recommendations Wall […]
AstraZeneca May Witness a Fall in 2017 Net Profit Margin
Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.
Keytruda’s Developments in June 2017
On June 12, 2017, Merck released updated data for Keytruda’s two phase III studies—KEYNOTE-183 and KEYNOTE-185—which evaluate Keytruda in combination with other drugs for the treatment of multiple myeloma.
Pfizer’s Profitability in 1Q17
Pfizer’s gross margin for 1Q17 was 81.0%, a 0.70% rise compared to 80.3% in 1Q16.
Analyzing Bristol-Myers Squibb’s Valuation on June 20
As of June 20, 2017, Bristol-Myers Squibb was trading at a forward PE multiple of ~18.0x—compared to the industry average of 16.0x.
SK Biotek to Acquire Manufacturing Facility in Swords, Ireland
In its press release on June 16, 2017, Bristol-Myers Squibb (BMY) announced that it entered into a definitive purchase agreement with SK Biotek.
What Drove Pfizer in 1Q17?
Growth drivers for Pfizer (PFE) include products contributing to operational growth, such as BMP2, Celebrex, Ibrance, Lyrica, and Xeljanz.
Inside Novartis’s Generics Business Now
Sandoz is also a leader in differentiated generics. Its contribution made up ~21% of Novartis’s total revenues in 1Q17.
GlaxoSmithKline’s Consumer Healthcare Segment in 1Q17
GlaxoSmithKline’s (GSK) Consumer Healthcare segment reported an operational growth of 2.0% to ~2.0 billion pounds in 1Q17.